Yahoo Web Search

Search results

  1. Learn why Corvus Pharmaceuticals, Inc. (CRVS) is a Zacks Rank 2 (Buy) stock and get the latest news, quote and history on Yahoo Finance.

  2. Get the latest Corvus Pharmaceuticals Inc (CRVS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

  3. BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate ...

  4. Apr 22, 2024 · 0.98%. $178.46M. CRVS | Complete Corvus Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

    • 19.47%
    • 12.57%
    • 34.62%
    • 13.07%
  5. A high-level overview of Corvus Pharmaceuticals, Inc. (CRVS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

    • Elutia Inc.
    • Biotechnology
    • 54
    • 70.88M
  6. Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China. (GlobeNewswire) Jan-01-22 07:43AM. Insiders who bought stock earlier this year lose -US$118k as Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) drops to US$112m. (Simply Wall St.)

  7. People also ask

  8. View the latest Corvus Pharmaceuticals Inc. (CRVS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

  1. People also search for